Glaukos Corporation is a leading ophthalmic medical technology and pharmaceutical company that develops and commercializes therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is best known for pioneering Micro-Invasive Glaucoma Surgery (MIGS) to disrupt the traditional glaucoma treatment paradigm. Its core products include the iStent family of micro-bypass stents, which are designed to enhance aqueous humor outflow and lower intraocular pressure in glaucoma patients. Beyond its leadership in MIGS, Glaukos has evolved into a multi-platform company with a robust portfolio of 'dropless' therapies, including sustained-release drug delivery systems like iDose TR, an intracameral procedural pharmaceutical designed to continuously deliver glaucoma drug therapy for up to three years. The company also offers bio-activated pharmaceutical therapies for corneal health, such as Photrexa and the iLink corneal cross-linking system. Glaukos generates the vast majority of its revenue from its Glaucoma segment, which includes both its surgical devices and sustained-release implants. The company markets its products through a direct sales organization in the United States and internationally, as well as through a network of international distributors.
